A Controlled Trial of High Dietary Fiber Intake on Serum Lipids
1 other identifier
interventional
50
1 country
1
Brief Summary
The study evaluates high fiber diet intake in patients with hyperlipidemia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2008
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2008
CompletedFirst Submitted
Initial submission to the registry
January 4, 2008
CompletedFirst Posted
Study publicly available on registry
January 15, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2013
CompletedMarch 9, 2017
March 1, 2017
3.5 years
January 4, 2008
March 7, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To test whether 30-40g of daily dietary fiber increases HDL, lowers total cholesterol and LDL levels in patients at 12 weeks
12 weeks
Secondary Outcomes (1)
To test whether Lipoprotein (a), triglyceride level, LDL: HDL ratio, fibrinogen, CRP, Urine f1 2 isoprostane and body weight will be lowered in patients after 12weeks.
12 weeks
Study Arms (1)
High Fiber Intake
EXPERIMENTALTwo 3/4 Cup servings of high fiber Uncle Sam cereal daily
Interventions
two 3/4 cup servings daily of Uncle Sam Cereal dietary instruction on high fiber diet
Eligibility Criteria
You may qualify if:
- All primary and secondary prevention patients aged 18 to 80 years with known or newly diagnosed isolated hypercholesteremia or combined hyperlipidemia.
You may not qualify if:
- Any patients with unstable angina, untreated hypothyroidism, uncontrolled diabetes, other endocrine or metabolic diseases not actively treated, acute inflammatory diseases, severe gastrointestinal diseases, chronic renal insufficiency (GFR\<30), end stage renal disease, liver disease or other severe diseases such as cancer, triglyceride level greater than 600 mg/dL, pregnant females, chronic use of systemic corticosteroid, or anticoagulants.
- Patients who were recently started or recently had their lipid lowering medications changed within the last 4 weeks will be excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- The Cleveland Cliniclead
- Attune Foodscollaborator
Study Sites (1)
Cleveland Clinic
Cleveland, Ohio, 44195, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Wael A Jaber, MD
The Cleveland Clinic
- PRINCIPAL INVESTIGATOR
Leslie Cho, MD
The Cleveland Clinic
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
January 4, 2008
First Posted
January 15, 2008
Study Start
January 1, 2008
Primary Completion
July 1, 2011
Study Completion
July 1, 2013
Last Updated
March 9, 2017
Record last verified: 2017-03
Data Sharing
- IPD Sharing
- Will not share